Caplin Point Announces Strong FY26 Results, Boosts Dividend Amid 13.2% Revenue Growth
Caplin Point Laboratories Limited, a pharmaceutical company, announced its financial performance for the quarter and year ended March 31, 2026. The company reported robust growth across its key markets, highlighting substantial increases in revenue and profits for the fiscal year.The Board of Directors also approved an Interim Dividend of INR 4.00 (200%) per equity share of face value INR 2 for the financial year ended March 31, 2026. The Record Date for determining shareholder eligibility for the dividend has been fixed as May 30, 2026.Financial Performance Snapshot
The financial results for the year ended March 31, 2026, reflect a healthy...